Pfizer Inc (PFE)
NYSE:PFE
Want to see PFE full AI Analyst Report?
PFE Stock Chart & Stats
$27.56
-$0.40(-1.47%)
At close: 4:00 PM EST
$27.56
-$0.40(-1.47%)
Day’s Range― - ―
52-Week Range$23.08 - $28.75
Previous CloseN/A
Volume12.20M
Average Volume (3M)36.14M
Market Cap
$146.08B
Enterprise Value$211.91B
Total Cash (Recent Filing)$13.07B
Total Debt (Recent Filing)$64.45B
Price to Earnings (P/E)19.4
Beta0.40
Next Earnings
Aug 04, 2026EPS Estimate
0.68Next Dividend Ex-DateN/A
Dividend Yield6.65%
Share Statistics
EPS (TTM)1.31
Shares Outstanding5,699,444,300
10 Day Avg. Volume33,078,423
30 Day Avg. Volume36,135,526
Financial Highlights & Ratios
PEG Ratio-4.31
Price to Book (P/B)1.64
Price to Sales (P/S)2.26
P/FCF Ratio15.59
Enterprise Value/Market Cap1.45
Enterprise Value/Revenue3.35
Enterprise Value/Gross Profit4.83
Enterprise Value/Ebitda12.51
Forecast
1Y Price Target
$29.17Price Target Upside5.83% Upside
Rating ConsensusHold
Number of Analyst Covering22
EPS Forecast (FY)2.96
Revenue Forecast (FY)$61.74B
Bulls Say, Bears Say
Bulls Say
Pipeline Clinical ProgressMultiple positive Phase III and mid-stage readouts materially increase the probability of near- and mid-term approvals. Successful clinical data across oncology and other areas strengthens the product funnel, reducing dependence on legacy/COVID revenues and supporting sustainable future revenue and margin expansion.
Margin Recovery And GuidanceReported adjusted gross margins near 76% and management guidance for mid-70s margins reflect a structurally stronger product mix and recent cost discipline. Sustained higher gross margins support durable operating profitability even as COVID sales normalize, improving long-term cash generation if maintained.
Launched/Acquired Product MomentumHigh single-quarter contribution and 22% operational growth from launches/acquisitions indicates effective commercialization and BD integration. This durable revenue stream diversifies cash flow, offsets LOE risk, and demonstrates the company's ability to scale new brands over multiple years.
Bears Say
Loss Of Exclusivity (LOE) HeadwindsMaterial patent expirations and LOE over the coming years represent a multi-billion-dollar structural headwind to revenue and margins. Even with some settlements, this multi-year erosion requires successful pipeline launches and M&A to replace lost sales, adding execution risk to the growth outlook.
Elevated LeverageLeverage materially higher than pre-2023 levels weakens financial flexibility for large investments, opportunistic M&A, or aggressive buybacks. With LOE and ongoing R&D needs, higher debt increases refinancing and allocation risk and constrains capital deployment over the next several years.
Weak Cash ConversionFree cash flow trailing net income and low operating cash flow relative to EBIT signal inefficient conversion of earnings into cash. This structural gap limits internally funded R&D and shareholder returns, making Pfizer more reliant on asset sales or external financing to cover strategic priorities.
Pfizer News
PFE FAQ
What was Pfizer Inc’s price range in the past 12 months?
Pfizer Inc lowest stock price was $23.08 and its highest was $28.75 in the past 12 months.
What is Pfizer Inc’s market cap?
Pfizer Inc’s market cap is $146.08B.
When is Pfizer Inc’s upcoming earnings report date?
Pfizer Inc’s upcoming earnings report date is Aug 04, 2026 which is in 62 days.
How were Pfizer Inc’s earnings last quarter?
Pfizer Inc released its earnings results on May 05, 2026. The company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.722 by $0.028.
Is Pfizer Inc overvalued?
According to Wall Street analysts Pfizer Inc’s price is currently Undervalued.
Does Pfizer Inc pay dividends?
Pfizer Inc pays a Quarterly dividend of $0.43 which represents an annual dividend yield of 6.65%. See more information on Pfizer Inc dividends here
What is Pfizer Inc’s EPS estimate?
Pfizer Inc’s EPS estimate is 0.68.
How many shares outstanding does Pfizer Inc have?
Pfizer Inc has 5,699,444,300 shares outstanding.
What happened to Pfizer Inc’s price movement after its last earnings report?
Pfizer Inc reported an EPS of $0.75 in its last earnings report, beating expectations of $0.722. Following the earnings report the stock price went up 0.572%.
Which hedge fund is a major shareholder of Pfizer Inc?
Currently, no hedge funds are holding shares in PFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pfizer Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$29.17 (5.83% Upside)
$29.17 (5.83% Upside)
Blogger Sentiment
Bullish
PFE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 53.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Bullish
Bullish news 79%
Bearish news 17%
Bearish news 17%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.52%
12-Months-Change
Fundamentals
Return on Equity
8.37%
Trailing 12-Months
Asset Growth
-0.20%
Trailing 12-Months
Company Description
Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
PFE Company Deck
PFE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational execution: a revenue and EPS beat, healthy underlying growth ex-COVID (~7%), substantial momentum from launched and acquired products (22% operational growth, $3.1B in Q1), multiple positive clinical readouts and meaningful strategic wins (Vyndamax settlement, favorable Belgian court ruling). Management balanced near-term challenges — LOE dynamics, COVID seasonality, higher accrued royalties and increased R&D spend — with clear actions to drive long-term growth (pipeline advancement, vaccine programs, manufacturing and cost-savings targets, BD capacity). Overall, positives around commercial performance, pipeline progress and legal/cash-flow clarity meaningfully outweigh the manageable near-term headwinds.View all PFE earnings summariesPFE Revenue Breakdown
97.79% Biopharma
0.00% PC1
0.00% Pfizer Ignite
2.21% Other business activities
PFE Stock 12 Month Forecast
Average Price Target
$29.17
▲(5.83% Upside)
Technical Analysis
Ownership Overview
0.02% Insiders
15.44% Mutual Funds
12.86% Other Institutional Investors
49.88% Public Companies and Individual Investors